Skip to main content
Premium Trial:

Request an Annual Quote

Products & Services: Oct 15, 2009


Prometheus Laboratories has launched three microRNA-based diagnostics: ProOnc TumorSource Dx, ProOnc Squamous Dx, and ProOnc Mesothelioma Dx.

According to the company, the first identifies the tissue-of-origin of a metastatic tumor; the second classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers; and the third differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

The tests were formerly known as miRview Mets, miRview Squamous, and miRview Meso, and were developed by Rosetta Genomics. In April, Rosetta agreed to license the US rights to the products to Prometheus (see RNAi News, 4/16/2009). The deal closed a few weeks later.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.